RxDoctor Payments Data

Ian Henderson, MD

Pulmonary Disease · Richardson, TXNPI 1144633124

Payments from drug & device makers

$705in general payments, 2019–2025

Across 32 payments — averaging $22.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sanofi$199
  • GSK$124
  • Regeneron Healthcare Solutions, Inc.$94
  • Insmed, Inc.$63
  • Electromed, Inc.$62
  • AstraZeneca$58
  • plus $105 from 5 others

What the payments were for

  • Food & beverage$705100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$705 in reported general payments places this provider in the 30th percentile of 904 pulmonary disease providers in Texas.

See all pulmonary disease providers in Texas

Medicare billing

Part B allowed, 2024
$286,205
Medicare patients
526
Services billed
2,304

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Dupixent PenDupilumab30$129,278
Trelegy ElliptaFluticasone/Umeclidin/Vilanter99$119,891
Stiolto RespimatTiotropium Br/Olodaterol Hcl61$45,190
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr47$40,161
Breo ElliptaFluticasone/Vilanterol36$27,530
Spiriva RespimatTiotropium Bromide14$15,900
Breztri AerosphereBudesonide/Glycopyr/Formoterol17$15,199
SymbicortBudesonide/Formoterol Fumarate29$7,435
Fluticasone-SalmeterolFluticasone Propion/Salmeterol25$5,931
BreynaBudesonide/Formoterol Fumarate11$5,092
Albuterol Sulfate HfaAlbuterol Sulfate111$4,976
Arnuity ElliptaFluticasone Furoate12$3,457
Wixela InhubFluticasone Propion/Salmeterol11$2,767
Ventolin HfaAlbuterol Sulfate14$1,129
Mycophenolate Mofetil14$696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Arnuity Ellipta$124$191,039194 claims
Boehringer IngelheimStiolto Respimat, Spiriva Respimat$16$61,09075 claims
AstraZenecaBreztri Aerosphere, Symbicort$58$22,63546 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 904 pulmonary disease providers in Texas.

Other pulmonary disease in Richardson

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →